Current and historical daily PE Ratio for SCYNEXIS Inc (
LTS:0L49
) from 2018 to May 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. SCYNEXIS stock (LTS:0L49) PE ratio as of May 27 2024 is 1.16.
More Details
SCYNEXIS Inc (LTS:0L49) PE Ratio (TTM) Chart
SCYNEXIS Inc (LTS:0L49) PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Total 1282
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| SCYNEXIS PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-28 | 1.1 | 2024-03-25 | 1.1 |
| 2024-05-24 | 1.1 | 2024-03-22 | 1.1 |
| 2024-05-23 | 1.1 | 2024-03-21 | 1.1 |
| 2024-05-22 | 1.2 | 2024-03-20 | 1.1 |
| 2024-05-21 | 1.3 | 2024-03-19 | 1.1 |
| 2024-05-20 | 1.3 | 2024-03-18 | 1.1 |
| 2024-05-17 | 1.4 | 2024-03-15 | 1.1 |
| 2024-05-16 | 1.2 | 2024-03-14 | 1.1 |
| 2024-05-15 | 1.1 | 2024-03-13 | 1.2 |
| 2024-05-14 | 0.9 | 2024-03-12 | 1.2 |
| 2024-05-13 | 1.0 | 2024-03-11 | 1.3 |
| 2024-05-10 | 1.0 | 2024-03-08 | 1.3 |
| 2024-05-09 | 0.9 | 2024-03-07 | 1.3 |
| 2024-05-08 | 0.9 | 2024-03-06 | 1.3 |
| 2024-05-07 | 0.9 | 2024-03-05 | 1.3 |
| 2024-05-06 | 0.8 | 2024-03-04 | 1.3 |
| 2024-05-03 | 0.8 | 2024-03-01 | 1.3 |
| 2024-05-02 | 0.9 | 2024-02-29 | 1.3 |
| 2024-05-01 | 0.8 | 2024-02-28 | 1.3 |
| 2024-04-30 | 0.8 | 2024-02-27 | 1.3 |
| 2024-04-29 | 0.9 | 2024-02-26 | 1.3 |
| 2024-04-26 | 0.8 | 2024-02-23 | 1.3 |
| 2024-04-25 | 0.7 | 2024-02-22 | 1.3 |
| 2024-04-24 | 0.8 | 2024-02-21 | 1.3 |
| 2024-04-23 | 0.8 | 2024-02-20 | 1.4 |
| 2024-04-22 | 0.7 | 2024-02-19 | 1.4 |
| 2024-04-19 | 0.7 | 2024-02-16 | 1.4 |
| 2024-04-18 | 0.7 | 2024-02-15 | 1.4 |
| 2024-04-17 | 0.7 | 2024-02-14 | 1.4 |
| 2024-04-16 | 0.7 | 2024-02-13 | 1.4 |
| 2024-04-15 | 0.7 | 2024-02-12 | 1.4 |
| 2024-04-12 | 0.8 | 2024-02-09 | 1.5 |
| 2024-04-11 | 0.8 | 2024-02-08 | 1.5 |
| 2024-04-10 | 0.8 | 2024-02-07 | 1.5 |
| 2024-04-09 | 0.8 | 2024-02-06 | 1.6 |
| 2024-04-08 | 0.8 | 2024-02-05 | 1.6 |
| 2024-04-05 | 0.9 | 2024-02-02 | 1.6 |
| 2024-04-04 | 0.9 | 2024-02-01 | 1.6 |
| 2024-04-03 | 0.8 | 2024-01-31 | 1.5 |
| 2024-04-02 | 0.7 | 2024-01-30 | 1.5 |
| 2024-04-01 | 0.7 | 2024-01-29 | 1.4 |
| 2024-03-29 | 0.7 | 2024-01-26 | 1.4 |
| 2024-03-28 | 0.7 | 2024-01-25 | 1.4 |
| 2024-03-27 | 1.1 | 2024-01-24 | 1.4 |
| 2024-03-26 | 1.1 | 2024-01-23 | 1.4 |
SCYNEXIS Inc (LTS:0L49) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
SCYNEXIS Inc
NAICS : 325412
SIC : 2834
ISIN : US8112922005
Description
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers